24/7 Wall Street
13 Jul 2026, 20:47 UTC · 7w ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
5 claims · each scored for market impact
Pfizer's COVID-related revenues are collapsing, with Comirnaty falling 59% and Paxlovid dropping 62%. — The loss of a primary revenue engine creates a fundamental valuation gap that requires high-risk pipeline success to fill.
-0.80Pfizer has paused share buybacks and faces $1.5 billion in losses from patent cliffs this year. — The cessation of buybacks and immediate patent losses reduce shareholder returns and pressure the bottom line.
-0.60Abbott Laboratories completed a $21 billion acquisition of Exact Sciences on March 23, 2026. — Significant expansion into cancer diagnostics (Cologuard/Cancerguard) provides a new high-growth revenue stream.
+0.50Continue reading
6 related stories
Top 3 movers · tap to explore
Abbott's Medical Devices segment grew 13.2% in Q1, driven by $2.08 billion in FreeStyle Libre revenue. — Strong double-digit growth in a core business segment supports a bullish case for the company's fundamental health.
Abbott insiders, including the CFO and a Director, have been purchasing shares near $92. — Insider buying typically signals that management believes the current market price is undervalued.
+0.30Which stocks this story touches
Despite a YTD price drop, the analyst views it as a stronger risk-adjusted setup with strong medtech growth, insider buying, and a strategic acquisition.
The analyst describes it as a 'value trap' due to collapsing COVID revenues, patent cliffs, and paused buybacks.
Mentioned only in the context of price targets without specific sentiment analysis in the main text.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
The Motley Fool
1d ago
